Lantheus Holdings (LNTH) Gains from Investment Securities (2020 - 2024)
Lantheus Holdings' (LNTH) quarterly Gains from Investment Securities came in at -$1.3 million in Q4 2024, down 747.0% year-on-year from $200000.0 in Q1 2024, and down 1394.0% on a QoQ basis from $100000.0 in Q2 2024.
Lantheus Holdings (LNTH) Gains from Investment Securities (2020 - 2024) Analysis & Trends
Lantheus Holdings (LNTH) has 5 years of Gains from Investment Securities data on file, last reported at -$1.3 million in Q4 2024.
- On a quarterly basis, Gains from Investment Securities fell 747.0% year-over-year to -$1.3 million in Q4 2024; TTM through Dec 2024 was -$994000.0, a 89.28% increase from a year earlier, with the FY2024 full-year figure at -$2.7 million, up 70.9% from the prior year.
- Gains from Investment Securities for Q4 2024 stood at -$1.3 million, down from $100000.0 in the prior quarter.
- Over the last five years, Gains from Investment Securities for LNTH reached as high as $43.9 million in Q4 2021 and fell as low as -$7.6 million in Q2 2023.
- Historically, Gains from Investment Securities has averaged $5.9 million across 5 years, with a median of $250000.0 in 2021.
- Across the five-year window, Gains from Investment Securities surged 6033.33% in 2022 and tumbled 747.0% in 2024, its largest moves.
- Year by year, Gains from Investment Securities stood at -$2.8 million in 2020, then jumped by 1667.86% to $43.9 million in 2021, then plunged by 78.82% to $9.3 million in 2022, then sank by 97.85% to $200000.0 in 2023, then plunged by 747.0% to -$1.3 million in 2024.
- Per Business Quant data, the three most recent Gains from Investment Securities figures were -$1.3 million in Q4 2024, $100000.0 in Q2 2024, and $200000.0 in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Lantheus Holdings | 7.04 Bn | 6.54 Bn | 230.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -1.29 Mn |
| Dec 31, 2024 | -1.29 Mn |
| Jun 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Dec 31, 2023 | 200,000.00 |
| Dec 31, 2023 | 200,000.00 |
| Sep 30, 2023 | -500,000.00 |
| Sep 30, 2023 | -500,000.00 |
| Jun 30, 2023 | -7.58 Mn |
| Jun 30, 2023 | -7.58 Mn |
| Mar 31, 2023 | -1.40 Mn |
| Mar 31, 2023 | -1.40 Mn |
| Dec 31, 2022 | 9.30 Mn |
| Dec 31, 2022 | 9.30 Mn |
| Sep 30, 2022 | -1.50 Mn |
| Sep 30, 2022 | -1.50 Mn |
| Jun 30, 2022 | 8.50 Mn |
| Jun 30, 2022 | 8.50 Mn |
| Mar 31, 2022 | 18.40 Mn |
| Mar 31, 2022 | 18.40 Mn |